New study tests which drug works best for rare lung condition
NCT ID NCT07406932
First seen Feb 15, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study looks at two types of drugs—JAK inhibitors and calcineurin inhibitors—as first treatments for lung scarring (interstitial lung disease) caused by antisynthetase syndrome. Researchers want to see which drug better improves lung function and helps people live longer over 12 months. The study will enroll 80 adults aged 18 to 75 who have not taken these drugs before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.